 |
|
|
|
 |
|
|
| Article 1 to 8 out of 8 concerning Solvay SA
|
-
Solvay Pharmaceuticals S.A. launches friendly bid to acquire Innogenetics
(04/29/2008)
Building on a successful R&D co-operation
Solvay Pharmaceuticals S.A., a subsidiary of Solvay, and Innogenetics N.V. jointly announced that Solvay Pharmaceuticals S.A. will make a conditional tender offer to acquire Innogenetics in a cash transaction valued at EUR 5.75 per share.Solvay ...
-
Innogenetics and Solvay Pharmaceuticals extend collaboration for biomarker discovery
(04/10/2008)
Innogenetics announced a 2-year extension of its longstanding research collaboration with Solvay Pharmaceuticals. Since November 1997, Solvay and Innogenetics have collaborated on a joint research program to explore new targets for Solvay's drug ...
-
Bionas Signs Service Contract with Solvay Pharmaceuticals
(10/02/2007)
Bionas GmbH announced that it has signed a service contract with Solvay Pharmaceuticals GmbH. The contract covers the metabolic profiling of several drug candidates identified in the context of Solvay´s obesity research program. Financial details ...
-
Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals announce receipt of an FDA action letter for bifeprunox
(08/14/2007)
Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals, a division of Wyeth, announced the receipt of an action letter from the U.S. Food and Drug Administration (FDA) in response to the New Drug Application (NDA) for bifeprunox, an atypical ...
-
Solvay's SLV 319 obesity candidate treatment advances in phase II clinical trials
(12/13/2006)
Triggering a milestone payment from co-development and co-commercialization partner Bristol-Myers Squibb
Solvay announced that a phase IIB study has started following a decision of the joint development committee for SLV319, which moved this obesity treatment candidate into further phase II clinical trials.SLV319 belongs to a novel class of agents ...
-
Bionas cell profiling device selected by Solvay Pharmaceuticals for Target Validation
(11/10/2006)
Bionas GmbH and Solvay Pharmaceuticals Research Laboratories announce that the Bionas(R) 2500 analyzing system has been recognized to be a valuable tool for target validation studies."It is known that angiotensin 1-8 (angiotensin II) acts via two ...
-
Solvay and Berna Biotech sign a license agreement for vaccine against Pseudomonas aeruginosa in Cystic Fibrosis patients
(08/04/2005)
Solvay Pharmaceuticals and Berna Biotech Ltd announced that they have signed a commercialization and license agreement for Aerugen®, a vaccine for the prevention of Pseudomonas aeruginosa (PA) infection in Cystic Fibrosis (CF) patients. The ...
-
Novozymes and Solvay to collaborate on digestive enzymes
(11/10/2004)
Solvay Pharmaceuticals and Novozymes A/S have entered a collaboration to develop new products for enzyme replacement therapy for patients suffering from pancreatic exocrine insufficiency, e.g., due to cystic fibrosis or after pancreatic surgery.It ...
|
|
|
|
|
Top